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Abstract
The bacterial endotoxin, lipopolysaccharide (LPS) has been associated with occupational
airway diseases with asthma-like symptoms and in acute exacerbations of COPD. The di-
rect and indirect effects of LPS on small airway reactivity have not been fully elucidated. We
tested the hypothesis that both in vitro and in vivo LPS treatment would increase contraction
and impair relaxation of mouse small airways. Lung slices were prepared from naïve Balb/C
mice and cultured in the absence or presence of LPS (10 μg/ml) for up to 48 h for measure-
ment of TNFα levels in conditioned media. Alternatively, mice were challenged with PBS or
LPS in vivo once a day for 4 days for preparation of lung slices or for harvest of lungs for
Q-PCR analysis of gene expression of pro-inflammatory cytokines and receptors involved
in airway contraction. Reactivity of small airways to contractile agonists, methacholine and
serotonin, and bronchodilator agents, salbutamol, isoprenaline and rosiglitazone, were as-
sessed using phase-contrast microscopy. In vitro LPS treatment of slices increased TNFα
release 6-fold but did not alter contraction or relaxation to any agonists tested. In vivo LPS
treatment increased lung gene expression of TNFα, IL-1β and ryanodine receptor isoform 2
more than 5-fold. However there were no changes in reactivity in lung slices from these
mice, even when also incubated with LPS ex vivo. Despite evidence of LPS-induced inflam-
mation, neither airway hyperresponsiveness or impaired dilator reactivity were evident. The
increase in ryanodine receptor isoform 2, known to regulate calcium signaling in vascular
smooth muscle, warrants investigation. Since LPS failed to elicit changes in small airway re-
activity in mouse lung slices following in vitro or in vivo treatment, alternative approaches
are required to define the potential contribution of this endotoxin to altered small airway re-
activity in human lung diseases.
Introduction
Inflammation in the distal lung plays a crucial role in many diseases including asthma and
chronic obstructive pulmonary disease (COPD). The bacterial endotoxin, lipopolysaccharide
(LPS) induces inflammation and has been associated with occupational airway diseases with
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asthma-like symptoms [1] and with acute exacerbations of COPD [2]. LPS is commonly pres-
ent within house dust, which contains a common asthma allergen, and a direct correlation
between levels of LPS in house dust and asthma severity has also been demonstrated [3]. Fur-
thermore, increased bacterial load in the airways of asthmatic patients impairs steroid respon-
siveness and bronchodilator responses to β-adrenoceptor agonists [4]. Despite the increasing
interest in contribution of small airways in the distal lung as sites of increased inflammation
and altered reactivity in asthma and COPD [5], the effects of LPS on their sensitivity to con-
strictor and dilator agents remains to be characterized.
LPS binds to and activates toll-like receptor 4 (TLR4) [6] to induce signaling via conven-
tional pro-inflammatory pathways such as: myeloid differentiation factor (MyD)88/NFκB;
phosphoinositide 3-kinase (PI3K)/Akt; and MAP/ERK/JNK/p38. Signaling through these
pathways leads an activation of Th2 cells involved in the adaptive immune system and subse-
quent release of cytokines, such as IL-6, TNFα and IL-1β. In addition to these conventional
pathways, LPS has been shown to increase anti-inflammatory cytokines such as IL-10 and IL-
22 [7], and activation of the arachidonic acid pathway leading to increased metabolites such as
PGE2 [8]. In the airways, TLR4 is located on smooth muscle, epithelial cells and on immune
cell types such as eosinophils and neutrophils [8,9], so has the potential to both directly and in-
directly affect airway contraction and relaxation.
Lung slice preparations containing small intrapulmonary airways more closely resemble the
morphology and functionality of the respiratory tract than isolated airways, and have been
used to assess the influence of inflammation on reactivity [10,11]. A single study using mouse
lung slices has shown that treatment with LPS for 24 h profoundly increased the expression
and release of the pro-inflammatory cytokines and chemokines, TNFα, IL-1β, IL-5, IL-12,
G-CSF, RANTES and eotaxin. [12]. Although in vitro treatment with LPS or some of these in-
dividual cytokines has been shown to alter tracheal responses to constrictor and dilator agents
[9,13–16], the effects of LPS on small airway reactivity in physiologically relevant lung slice
preparations remains to be determined.
LPS is commonly used to induce systemic and lung inflammation in mice and rats. Of rele-
vance to the current study, intranasal administration of LPS to mice over four consecutive days
induces in vivo airways hyperresponsiveness (AHR) to methacholine (MCh), mediated through
the conventional MyD88-dependent signaling pathway and associated with increased neutro-
phils and total cell number in the BAL fluid [17]. Assessment of in vitro reactivity in lung slices
from mice treated with LPS in vivo has the potential to define the influence of this LPS-induced
inflammatory cell recruitment and cytokine production on small airways.
The aim of this study was to examine the effects of LPS on small airway reactivity using lung
slices from naïve mice treated with LPS in vitro and lung slices from LPS-treated mice to test
the hypothesis that LPS treatment would increase contraction and impair dilator responses in
small airways. Airway contraction to MCh and serotonin (5-HT) and relaxation to β-adreno-
ceptor agonists and rosiglitazone (RGZ), a PPARγ agonist recently described as a novel bron-
chodilator [18], were assessed. Although LPS-induced inflammation was established both in
vitro and in vivo, reactivity to all of the agents tested was not markedly altered. The experimen-
tal conditions that demonstrate AHR and impaired dilator responses in small airways in re-
sponse to LPS remain to be defined.
Methods
Materials and solutions
Pentobarbitone sodium anaesthetic (Cenvet, Australia); ultra pure low melting point agarose,
10 x Hank’s Balanced Salt Solution (HBSS), 1 M HEPES buffer solution, Dulbecco’s Modified
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Eagle Medium (DMEM) (GIBCO/Invitrogen, Australia); rosiglitazone (Cayman); acetyl-
β-methacholine chloride (MCh), isoprenaline hydrochloride (ISO), lipopolysaccharide (LPS),
penicillin-streptomycin solution, salbutamol hemisulfate salt (SALB), serotonin hydrochloride
(5HT) (Sigma-Aldrich, Australia).
LPS (Escherichia Coli serotype 026:B6: Sigma Aldrich Australia) stocks (1 mg/ml) were
made up on day of use in either 1 x PBS for in vivo experiments or DMEM supplemented with
penicillin-streptomycin for lung slice incubations.
Ethics statement
All experiments were approved by the Animal Experimentation Ethics Committee of The Uni-
versity of Melbourne (application numbers 1011608, 1212485) and Murdoch Children’s Re-
search Institute (MCRI, application numbers A738) and conducted in compliance with the
guidelines of the National Health and Medical Research Council (NHMRC) of Australia.
Animals
Specific pathogen-free male or female Balb/c mice (6–12 weeks) were obtained from the Ani-
mal Resource Centre Pty. Ltd. (Perth, Australia) or the Walter and Eliza Hall Institute for
Medical Research respectively. Mice were housed at 20°C on a 12 h day/night cycle and fed a
standard sterile diet of mouse chow with water allowed ad libitum.
In vivo LPS administration
Female mice were anaesthetized by methoxyflurane (Medical Developments International Ltd,
Australia) inhalation and 50 μl of PBS or LPS (5 μg of LPS in 50 μl of PBS) administered intra-
nasally as previously described [19] at 9 am every day for 4 consecutive days.
Lung slice preparation and in vitro LPS treatment
Lung slices were prepared as previously described [18,20,21]. Briefly, naïve male mice were
culled by overdose of sodium pentobarbitone (0.4 ml) while LPS-treated female mice were eu-
thanized with 0.4 ml of Avertin (2.5%) one day after final LPS administration. The trachea was
cannulated (20 G Intima, BD Scientific) for inflation of the lungs by injecting approximately
1.4 ml of liquid agarose (44°C, 2% in HBSS supplemented with HEPES) followed by a bolus of
air. After solidifying the agarose in 1 x HBSS/HEPES at 4°C for 20–30 min, the left lobe was iso-
lated and mounted in a vibratome (VT 1000S, Leicamicrosystems) and bathed in 1 x HBSS/
HEPES maintained at 4°C by surrounding the stage with ice.
Lung slices (150 μm) from all mice were serially sectioned and placed into a 24 well plate
containing DMEM supplemented with 1% penicillin-streptomycin solution, 1 slice per well.
Slices were then incubated in the absence or presence of 10 μg/ml LPS for up to 48 h. This con-
centration of LPS was used as an in vitro stimulus consistent with other related studies examin-
ing its inflammatory effects on mouse tracheal reactivity [8].
Lung slice mounting and microscopy
Following incubation, slices were placed into HBSS/HEPES buffer prior to assessment of reac-
tivity. Phase contrast microscopy was used to observe the lung slices on an inverted microscope
(Diaphot 300; Nikon) using 10 x objective lens, zoom adaptor, reducing lens and camera (CCD
camera model TM-62EX; Pulnix). Individual slices were placed on a 45 x 50 mm coverglass
and covered in fine wire mesh (210 μm openings; Small Parts Inc.) with a small hole cut over
an airway.
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A custom-made perfusion chamber was created by running a channel of silicon along either
side of the lung slice-nylon mesh preparation and covered with an additional 11 x 30 mm
coverglass (resulting in approximately 100 μL volume within the channel). A single airway
(200–400 μm) within each lung slice was selected for experimentation. Airway viability was es-
tablished based on the presence of an intact layer of epithelial cells displaying ciliary activity
and confirmation of reactivity to a constrictor agent.
Images showing decreases in airway lumen area in response to MCh and 5HT and relaxa-
tion of airways pre-contracted with 5HT in response to salbutamol, isoprenaline and rosiglita-
zone were recorded every 2 sec (0.5 Hz) using VideoSavant imaging software (VideoSavant; IO
Industries, London, ON, Canada) and analysed using NIH/Scion (Scion Corp., Torrance, CA).
A grey scale threshold distinguished between airway lumen and parenchyma for pixel counts.
Representative images of a MCh contraction and area analysis are shown in Fig 1.
Measurement of TNF-α, IL-10 and PGE2
Conditioned media from slices prepared from naïve mice was stored at -80°C. TNF-α and IL-
10 were measured by ELISA according to the manufacturer’s instructions (R&D Systems,
Minneapolis, Minnesota, USA). The ranges of detection were between 10.9–700 pg/ml and
15.6–1000 pg/ml for TNF-α and IL-10 respectively. PGE2 was measured by Enzyme Immuno-
assay (EIA) (Cayman Chemicals/Sapphire Bioscience). The range of detection of PGE2 was be-
tween 15–1000 pg/ml.
Q-PCR
Lungs were harvested from PBS- and LPS-treated mice for Q-PCR analysis as previously de-
scribed [22].
Fig 1. MCh contraction in mouse lung slices.Representative images of a single airway taken at the end of each 5 min perfusion with increasing
concentrations of MCh. Representative trace of a MCh contraction recorded at 2 sec intervals as a % of the initial airway lumen area and shown over a total of
40 min perfusion.
doi:10.1371/journal.pone.0122069.g001
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Statistical analysis
All data were expressed as mean ± SEM, where each n represents one slice or lung lysate sample
per mouse. Statistical analysis was performed using GraphPad PrismTM (version 5.0c) with
P<0.05 accepted as being statistically significant. For lung slice experiments, contraction data is
presented as a % of the initial airway lumen area to correct for differences in airway size, while
responses to dilators are expressed as % relaxation of pre-contracted airways. Concentration-re-
sponse curves were fitted to obtain pEC50 and maximum values and analysed by unpaired
t-tests or one-way ANOVA with Bonferroni’s post hoc test where appropriate. For TNFαELISA
data and PGE2 EIA data were compared using non-parametric Wilcoxon matched pairs test.
Q-PCR data was analysed using the ΔΔCt method compared to 18S as the control and analysed
by Mann-Whitney non-parametric tests.
Results
Inflammatory effect of LPS treatment in vitro
To assess whether LPS treatment was able to elicit an inflammatory response in lung slices, in-
dividual slices were incubated with LPS (10 μg/ml) for 2, 18 or 48 h. These timepoints were
selected to observe potential LPS-induced changes during early and resolution phases of the in-
flammatory response, with a maximum of 48 h to minimise any effect due to loss of tissue
viability. Mouse TNFα levels in conditioned media increased in a time-dependent manner (ap-
proximately 5-fold by 18 h, 6-fold by 48 h), confirming that LPS increases this pro-inflammato-
ry cytokine (48 h: 175.6±65.9 pg/ml) (Fig 2).
Effect of LPS treatment in vitro on bronchoconstrictor responses in lung
slices
Having confirmed that in vitro exposure to LPS induced a marked inflammatory response, the
direct effects of LPS on airway reactivity over the same time course were assessed. Slices were
incubated with LPS (10 μg/ml) for up to 48 h, prior to perfusion with either MCh or 5HT
(Fig 3). Both contractile agonists elicited concentration-dependent contraction with similar po-
tency (Fig 3 and Table 1). Incubation with LPS did not affect MCh-induced contraction at any
time-point (Fig 3 and Table 1). The potency of 5HT was not affected by LPS, but maximal
Fig 2. In vitro LPS treatment increases TNFα in conditioned media frommouse lung slices. Lung slices
from naïve mice were cultured in the absence or presence of LPS (10 μg/ml) for 2, 18 or 48 h. Mouse TNFα
levels were measured by ELISA (n = 6–20, where n represents conditioned media from one slice per mouse).
Data is expressed as mean ± S.E.M. *P<0.05, non-parametric Wilcoxon matched pairs test, one tailed.
doi:10.1371/journal.pone.0122069.g002
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5HT-mediated contraction was slightly decreased at 2 and 18 h (P = 0.09, 0.03 respectively)
and increased after 48 h (P = 0.11) (Fig 3 and Table 1).
In addition to measurement of pro-inflammatory cytokines, IL-10 levels in conditioned
media from LPS-treated slices were assayed. This was to determine if LPS could be releasing
anti-inflammatory cytokines to oppose inflammation-induced changes in reactivity. Levels of
IL-10 were not detectable under control conditions, and were not increased by up to 48 h incu-
bation with LPS (n = 6–8, data not shown).
Fig 3. In vitro LPS treatment does not increase contraction to MCh and 5HT in mouse lung slices. Lung slices from naïve mice were cultured in the
absence (open symbols) or presence (closed symbols) of LPS (10 μg/ml) for 2, 18 or 48 h for MCh (left hand side) or 5HT (right hand side) concentration-
response curves. Average small airway contractile responses are expressed as % initial airway lumen area (mean ± S.E.M) for n = 3–4 where n represents
paired slices from one mouse.
doi:10.1371/journal.pone.0122069.g003
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PGE2 release from the lung slices in response to LPS was also assayed, to determine if in-
creased PGE2 could be opposing any cytokine-induced effects on reactivity. In addition, the
effects of AH6809 (3 μM), an antagonist to the prostaglandin (EP) 1/2 receptors on airway
smooth muscle, were assessed. These receptors have been previously shown to mediate relaxa-
tion to PGE2 in mouse lung slices [21]. There was no difference in concentration-response
curves to 5HT in LPS-treated slices incubated in the absence or presence of AH6809 (Fig 4). In
addition, LPS did not increase PGE2 release into the media of individual lung slices, as mea-
sured by PGE2 EIA (Fig 4).
Effect of LPS treatment in vitro on bronchodilator responses in lung
slices
To assess whether airway relaxation was impaired, despite the lack of marked changes in con-
tractile responses to MCh and 5HT following LPS treatment, lung slices were pre-incubated
with LPS for 48 h prior to assessment of dilator responses (Fig 5). The level of pre-contraction
with 300 nM 5HT was similar in control and LPS-treated slices (~40% reduction in airway
lumen area). SALB only caused partial relaxation at concentrations up to 10 μM (maximum re-
laxation, 52.1±14.9%), which was unaffected by treatment with LPS (Fig 5). RGZ elicited full
relaxation but was less potent than SALB, requiring 100 μM to reverse the contraction to 5HT
(RGZ pEC50: 4.4±0.2). Relaxation to RGZ was slightly increased following 48 h incubation
with LPS (RGZ pEC50: 5.0±0.3, P = 0.13) (Fig 5). Incubation with LPS for only 2 h also had no
effect on dilator responses to either SALB or RGZ (data not shown).
Table 1. The effect of in vitro LPS treatment on potency andmaximum contraction to MCh and 5HT.
2 h 2 h 18 h 18 h 48 h 48 h
Media LPS Media LPS Media LPS
MCh pEC50 7.1±0.1 7.3±0.1 7.3±0.1 7.2±0.1 7.4±0.1 7.4±0.1
MCh maximum 59.6±6.4 72.3±5.1 66.4±3.4 60.6±5.6 43.5±10.1 57.0±12.2
5HT pEC50 7.2±0.1 7.1±0.2 7.9±0.03 7.8±0.07 7.3±0.2 7.1±0.2
5HT maximum 54.3±3.5 42.6±0.9 48.8±5.0 35.5±5.2* 29.3±5.7 52.2±5.5
Slices from naive mice were incubated in the absence or presence of LPS (10 μg/ml, 2–48 h). pEC50 and maxima were obtained from ﬁtted individual
concentration-response curves. Maximum represented as a % reduction in airway lumen area. n = 3–4 per group.
*P<0.05 cf media 18 h.
doi:10.1371/journal.pone.0122069.t001
Fig 4. Contraction to 5HT is not altered by AH6809, EP1/2 receptor antagonist, and in vitro LPS treatment does not increase PGE2 in conditioned
media frommouse lung slices. Lung slices from naïve mice were incubated for 48 h in the absence and presence of LPS (10 μg/ml) and/or AH6809 (3 μM)
prior to 5HT concentration-response curves. Average small airway contractile responses are expressed as % initial airway lumen area (mean ± S.E.M) for
n = 3–7 where n represents one slice per mouse. Lung slices were incubated in the absence and presence of LPS (10 μg/ml) for 2, 18 or 48 h. Conditioned
media was stored at -80°C prior to PGE2 EIA. PGE2 levels (mean ± S.E.M) are for n = 4–10 where n represents conditioned media from one slice per mouse.
doi:10.1371/journal.pone.0122069.g004
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Inflammatory effect of LPS treatment in vivo
Minimal effects on airway reactivity were observed following in vitro treatment of lung slices,
despite evidence of increased inflammatory cytokine levels in conditioned media. To determine
whether in vivo LPS treatment was required to alter reactivity, lung slices were prepared from
mice treated with LPS for 4 days. To confirm that this in vivo LPS treatment regimen was able
to elicit an inflammatory response in these mice, gene expression of the pro-inflammatory cy-
tokines was measured in the lungs. IL-1β and TNFα were increased greater than 5-fold relative
to PBS-treated controls (Fig 6A and 6B).
Effect of LPS treatment in vivo and ex vivo on bronchoconstrictor and
bronchodilator responses in lung slices
To assess the effects of LPS-induced lung inflammation in vivo on airway reactivity, lung slices
were prepared following 4 day treatment with PBS or LPS in vivo. Contraction to MCh and
5HT was similar in lung slices from PBS- and LPS-treated mice, with no differences in potency
or maximum reduction in lumen area (Fig 7A, 7B and Table 2). To determine whether
Fig 5. Partial relaxation to salbutamol or full relaxation to rosiglitazone in mouse lung slices is not impaired by in vitro LPS treatment. Lung slices
from naïve mice were incubated for 48 h in the absence and presence of LPS (10 μg/ml). Small airways in mouse lung slices were pre-contracted with 300nM
5HT prior to perfusion with SALB (upper panel) or RGZ (lower panel). Average small airway contractile responses (left hand side) are expressed as % initial
airway lumen area. Responses to SALB and RGZ (right hand side) are expressed as % relaxation of the submaximal pre-contraction. Responses
(mean ± S.E.M) are shown for SALB (n = 3–4) and RGZ (n = 4–6) where n represents paired slices from one mouse.
doi:10.1371/journal.pone.0122069.g005
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sustained exposure to LPS ex vivo was required to influence reactivity, lung slices prepared
from PBS- and LPS-treated mice were also treated with LPS (10 μg/ml) for 48 h. However, this
did not affect contraction to either agonist (5HT, Fig 7C, 7D and Table 2; MCh Table 2).
Bronchodilator responses were also assessed in lung slices from PBS- and LPS-treated mice.
Airways were pre-contracted with 300 nM 5HT prior to addition of ISO (10 μM) or RGZ
(100 μM), concentrations previously shown to be maximally effective in slices from naïve mice.
There were no differences between the bronchodilator responses in the LPS-treated groups
compared to the PBS-treated groups with either agent tested, with ISO causing partial relaxa-
tion and RGZ causing full relaxation (Fig 8).
Effect of LPS treatment in vivo on expression of genes related to
contraction
To assess the effect of LPS treatment in vivo on gene expression of receptors for MCh, 5HT, the
G proteins coupled to these receptors and their downstream signaling receptors IP3R and RyR,
whole lung lysates were prepared from mice treated with LPS in vivo for 4 days and PBS-
treated controls. There was significant upregulation of the muscarinic M2 receptor, but there
were no changes in the muscarinic M3 receptor, 5HT2A receptor, or their G proteins. There
were also no changes in the IP3R isoforms and RyR isoform 1 and 3, however there was 5-fold
upregulation of RyR isoform 2 (Table 3).
Discussion
This study characterised the potential influence of LPS-induced inflammation on small airway
responses to constrictor and dilator agents by measuring changes in airway lumen area in lung
slice preparations. Slices prepared from naïve mice were incubated with LPS for up to 48 h in
vitro and slices were also obtained from mice treated with LPS daily for 4 days in vivo. Al-
though LPS treatment in vitro caused the release of TNFα, an inflammatory cytokine known to
contribute to AHR, changes in reactivity to constrictors were minimal. In vivo treatment with
LPS elevated gene expression of pro-inflammatory cytokines. Despite this, there were no
changes in the in vitro airway contraction in slices from these LPS-treated mice, even when
Fig 6. In vivo LPS treatment increases gene expression of pro-inflammatory cytokines in whole lung
lysates.Mice were treated with PBS or LPS once a day intranasally for four days. On day 5, whole lungs from
PBS- and LPS-treated mice were homogenized and RNA was extracted using a Qiagen kit. Following
conversion of RNA to cDNA, Q-PCR was performed using Taqman primers. All data was analysed by the
ddCt method, using 18S as the control gene. A) IL-1β expression and B) TNFα expression. All data is
presented as gene expression relative to PBS (mean ±S.E.M). PBS n = 3, LPS n = 5 where n represents one
lung lysate sample per mouse measured in triplicate. *P<0.05 Mann-Whitney non-parametric test compared
to PBS.
doi:10.1371/journal.pone.0122069.g006
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Fig 7. Constrictor responses to 5HT and MCh in lung slices from PBS and LPS-treated mice treated ex vivowith LPS.Mice were treated with PBS
(open circles) or LPS (closed circles) once a day intranasally for four days. On day 5, lung slices were prepared and incubated in culture media overnight.
Concentration-response curves were prepared to A) MCh and B) 5HT. Additional slices from PBS- and LPS-treated mice were incubated in media or LPS
(10 μg/ml for 48 h, shown in blue). Concentration-response curves were prepared for 5HT C) PBS-treated mice ± LPS, D) LPS-treated mice ± LPS. All data is
expressed as % initial airway lumen area (mean ± S.E.M), n = 3–4 where n represents one slice per mouse.
doi:10.1371/journal.pone.0122069.g007
Table 2. The effect of in vivo LPS treatment on potency andmaximum contraction to MCh and 5HT.
PBS PBS LPS in vivo LPS in vivo
Media + LPS in vitro Media + LPS in vitro
MCh pEC50 7.2±0.2 7.6±0.1 7.0±0.1 6.7±1.6
MCh maximum 22.0±11.0 23.3±4.7 27.7±5.5 23.7±15.8
5HT pEC50 7.2±0.4 7.7±0.1 7.4±0.2 7.2±0.1
5HT maximum 22.1±8.9 48.9±12.9 38.3±10.4 42.2±11.4
Slices were obtained from PBS- and LPS-treated mice, and incubated in the absence or presence of LPS (10 μg/ml, 48 h). pEC50 and maxima were
obtained from ﬁtted individual concentration-response curves. Maximum represented as a % reduction in airway lumen area. n = 3–4 per group.
doi:10.1371/journal.pone.0122069.t002
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Fig 8. Bronchodilator responses in lung slices frommice treated with PBS or LPS for four days. Lung
slices were prepared from PBS- (open bars) or LPS- (closed bars) treated mice. Airways were pre-contracted
with 5HT (300 nM) prior to addition of ISO (10 μM, green) or RGZ (100 μM, blue). Upper panel: representative
trace of the protocol of pre-contraction and relaxation to each dilator agent. Lower panel: grouped data of
the bronchodilator responses are expressed as a % relaxation of the sub-maximal pre-contraction
(mean ± S.E.M) for n = 3–4 where n represents one slice per mouse.
doi:10.1371/journal.pone.0122069.g008
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they were also exposed to LPS in vitro. We report here for the first time that small airway re-
sponses to bronchodilators in mouse lung slices were similarly unaffected by LPS-induced
inflammation.
Bacterial infections in patients with chronic lung diseases, such as asthma and COPD, can
severely impact on their quality of life and lead to hospital admissions. We set out to assess
whether exposure to LPS, a common bacterial toxin used to mimic bacterial infections in ro-
dents, could cause inflammatory changes and alter airway reactivity in mouse small airways.
Initially, lung slices were incubated in the absence or presence of LPS in vitro. TLR4, the re-
ceptor for LPS, is present on airway smooth muscle and epithelial cells [8,9], and signaling
through this receptor results in an up-regulation and release of multiple pro-inflammatory cy-
tokines [23]. Here, we showed a time-dependent increase in TNFα release from lung slices fol-
lowing 2 and 18 h treatment with LPS, with a further modest increase up to 48 h.
We then assessed the potential influence of this LPS-induced inflammation, evidenced by
the accumulation of TNFα on small airway reactivity. As previously reported, both MCh and
5HT contracted small airways in untreated lung slices [24]. However, changes in small airway
reactivity to contractile agonists were not detected, irrespective of the levels of TNF03B1. This
suggests that in vitro AHR can not be induced in mouse lung slices either during the initiation,
progression or maintenance of the LPS-induced inflammatory response occurring over 48 h.
In untreated lung slices, the β2-adrenoceptor agonist SALB elicited only partial relaxation,
while RGZ was less potent but able to fully reverse a submaximal 5HT-mediated contraction.
RGZ has previously been shown to exert this acute dilator action via a PPARγ-independent
mechanism involving inhibition of calcium oscillations and sensitivity [18,20]. LPS treatment
in vitro did not affect dilator responses to either SALB or RGZ.
Previous experiments carried out in isolated mouse and rabbit trachea have demonstrated
that LPS treatment in vitro can induce AHR to bradykinin and 5HT, but not carbachol as well
as impair dilator responses to isoprenaline [25]. These agonist-specific effects are consistent
with our findings for MCh, where LPS had no effect. The modest changes on the response to
Table 3. The effect of in vivo LPS treatment on gene expression in whole lung lysates.
Gene PBS LPS
Muscarinic M3 receptor 1.04 ± 0.20 1.55 ± 0.32
5HT2A receptor 1.07 ± 0.26 1.06 ± 0.20
Gnai isoform 1 1.01 ± 0.11 1.22 ± 0.13
Gnai isoform 2 1.05 ± 0.24 0.69 ± 0.11
Gnai isoform 3 1.03 ± 0.18 0.87 ± 0.11
Gnaq 1.04 ± 0.20 1.18 ± 0.19
RyR isoform 1 1.12 ± 0.38 0.57 ± 0.08
RyR isoform 2 1.09 ± 0.31 4.96 ± 0.99 *
RyR isoform 3 1.01 ± 0.32 1.57 ± 0.35
IP3R isoform 1 1.01 ± 0.09 1.18 ± 0.10
IP3R isoform 2 1.00 ± 0.01 1.20 ± 0.18
IP3R isoform 3 1.02 ± 0.15 0.77 ± 0.11
Lung lysates were obtained from PBS- and LPS-treated mice for Q-PCR analysis using Taqman probes for
M3 (chrm3) receptors, serotonin 2A receptors, G proteins, ryanodine receptors (RyR) and inositol
trisphosphate (IP3) receptors. All data is expressed as mean ± SEM.
* P<0.05 unpaired t-test. PBS n = 3, LPS n = 5 per group.
doi:10.1371/journal.pone.0122069.t003
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5HT and salbutamol in the current study in comparison to those seen in trachea suggest that
the effects of LPS may be less pronounced in smaller airways.
There are several other possible reasons for the lack of effect of LPS on reactivity in this set-
ting. Although LPS treatment of lung slices has previously been shown to cause release of mul-
tiple pro-inflammatory cytokines known to induce in vitro hyperresponsiveness [23], their
combined levels in the conditioned media may have been too low to increase contractile re-
sponses to MCh or have marked effects on the response to 5HT. In the current study, the accu-
mulated levels of TNFα released from a single lung slice over 48 h were> 100 times lower than
the TNFα concentration shown to increase contraction to acetylcholine in isolated human air-
ways after 16 h exposure [14]. We have previously shown that 48 h incubation with 50 ng/ml
TNFα had no effect on mouse airway contraction in lung slices [26], suggesting that mouse
small airways may also be less sensitive to TNFα than human airways. Given the levels of
TNFα detected in the current study, it is also unlikely that levels of other individual cytokines
previously shown to be released in response to LPS [27], and demonstrated to induce in vitro
AHR to MCh in mouse lung slices, such as IL-17A (100 ng/ml) [28], would have accumulated
at sufficient levels to alter reactivity.
Alternatively, other endogenous mediators produced by lung slices in response to LPS may
have opposed inflammation-induced changes in small airway reactivity. To address this possi-
bility, we measured IL-10, a potent anti-inflammatory cytokine, in conditioned media collected
after LPS treatment of lung slices in vitro. It is well documented that LPS can also increase lev-
els of PGE2, a metabolite of the arachidonic acid pathway, which can inhibit inflammatory cy-
tokine release from airway smooth muscle [29] and well as oppose contraction in small airways
in mouse lung slices [21]. However, increased levels of IL-10 or PGE2 were not detected in the
media following LPS treatment, possibly due to the limited production from the small volume
of lung slice tissue relative to the conditioned media volume. Further investigation of the cyto-
kine profile and their levels in conditioned media from lung slices following LPS treatment
may reveal whether the overall production of cytokines from lung slices mediated through sig-
nalling via TLR4 is producing a balance of pro- and anti-inflammatory cytokines, minimizing
potential changes in airway reactivity.
Given these findings, we do not believe that a lower concentration of LPS in vitro would
have had altered either contraction or relaxation, since we attribute this lack of effect to either
the difference in sensitivity of large and small airways to this inflammatory stimulus, or the
minimal production of cytokines known to alter reactivity by lung slice preparations. Increas-
ing the concentration of LPS in vitro to produce a greater pro-inflammatory response in lung
slices may not be feasible, given that LPS can be toxic to cells. To provide a stronger stimulus,
we assessed the effects of LPS given repeatedly and over a longer period in vivo prior to assess-
ment of small airway reactivity ex vivo. We utilized a model in which 4-day exposure to LPS in-
duces airway hyperresponsiveness, as measured in vivo using direct plethysmography [17]. In
this more clinically relevant model, we hypothesized that LPS treatment in vivo could recruit
inflammatory cells to the airways, to allow for subsequent release of pro-inflammatory cyto-
kines from both inflammatory and resident cells, leading to changes in contraction and relaxa-
tion of small airways that would be maintained in vitro.
To validate the effects of in vivo LPS treatment, we initially assessed whether there were any
overall changes in the expression of pro-inflammatory cytokines in total lung. As predicted,
there were marked increases in gene expression for IL-1β and TNFα after LPS treatment, con-
firming an inflammatory response consistent with previous studies [19]. However, there were no
LPS-induced changes in expression of the muscarinic M3 or 5HT2A receptors that mediate con-
traction to MCh and 5-HT respectively. Similarly, the gene expression of receptors associated
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with downstream signaling for these contractile agonist receptors, namely IP3R isoforms 1–3
and RyR isoforms 1 and 3, were also similar in lungs from PBS- and LPS-treated mice.
Our results showed a 5-fold increase in the expression of RyR isoform 2 after LPS treatment
in vivo. Based on previous studies, this isoform is more likely to be localized in vascular rather
than airway smooth muscle in the lung [30]. It would therefore be of interest to conduct studies
to assess the impact of this LPS-induced increase in RyR isoform 2 expression on vascular reac-
tivity, also utiliising the lung slice method where these responses can be assessed [31].
Although contractile receptor expression was unchanged following LPS treatment in vivo,
we assessed whether in vitro small airway reactivity had been altered in this model by other in-
flammatory mechanisms. We also treated slices from PBS- and LPS-treated mice with LPS to
determine whether continued exposure to an inflammatory stimulus may be required to elicit
or maintain changes in airway reactivity.
Given the evidence of in vivo hyperresponsiveness to MCh in this model [17], we predicted
that small airway contraction to contractile agonists would be increased after LPS treatment in
vivo and subsequent LPS incubation in vitro. However, we found no changes in the potency or
maximum contraction either MCh or 5HT. While there were no changes in the bronchodilator
efficacy of RGZ, there was a trend to increased relaxation to ISO at the single concentration test-
ed after LPS treatment. This finding requires confirmation in full concentration-response curves,
as ISO has very variable responses at single concentrations in mouse small airways [18,20].
We have previously reported on the differential effects of an inflammatory stimulus on large
and small airway reactivity in the lung. In a chronic ovalbumin-induced model of allergic air-
ways disease, in vivo hyperresponsiveness to MCh was evident in tracheal preparations in vitro,
but not in small airways in lung slices [26]. However, these differential effects were attributed
to the potential influence of small airway fibrosis and parenchymal interactions to oppose air-
way narrowing and inflammation-induced hyperresponsiveness in the distal lung. In the ab-
sence of remodeling changes with relatively short term LPS treatment in the current study,
alternative mechanisms remain to be elucidated.
In summary, we have confirmed that treating lung slices with LPS can increase levels of
TNFα, indicating that lung slices can be used as tools to assess immunomodulation of airway
cells resident within functional tissue. We propose that the lack of effect of in vitro LPS treat-
ment on small airway reactivity in this experimental setting may be due to the limited produc-
tion of pro-inflammatory mediators to act in an autocrine fashion rather than increased levels
of potential anti-inflammatory mediators. While treatment with LPS in vivo caused lung in-
flammation, as evidenced by increased expression of IL-1β and TNFα, there was no evidence
of increased small airway contraction or impaired relaxation. The LPS-induced increase in
RyR2 which predominates in the vascular smooth muscle warrants further investigation, as
this may contribute to altered vascular reactivity in the inflamed lung. Despite causing inflam-
mation, LPS failed to exert demonstrable effects on small airway reactivity within mouse lung
slices. Alternative approaches are required to define the potential contribution of endotoxin-
induced inflammation to impaired small airway function in inflammatory lung diseases such
as asthma and COPD.
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